Cargando…
Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma
This study aimed to define the maximum-tolerated dose (MTD) of fixed dose rate (FDR) of gemcitabine (2′-2′-difluorodeoxycitidine) infusion with circulating haemopoietic progenitor support and to evaluate the activity of the treatment. Secondary end points were pharmacokinetic of gemcitabine and difl...
Autores principales: | Bengala, C, Guarneri, V, Giovannetti, E, Lencioni, M, Fontana, E, Mey, V, Fontana, A, Boggi, U, Del Chiaro, M, Danesi, R, Ricci, S, Mosca, F, Del Tacca, M, Conte, P F |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361486/ https://www.ncbi.nlm.nih.gov/pubmed/15986033 http://dx.doi.org/10.1038/sj.bjc.6602673 |
Ejemplares similares
-
Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile
por: Giovannetti, E, et al.
Publicado: (2005) -
In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients
por: Mey, V, et al.
Publicado: (2006) -
Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells
por: Paolo, A Di, et al.
Publicado: (2001) -
Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells
por: Bocci, G, et al.
Publicado: (2005) -
Inhibitors of Haemopoietic Cell Proliferation?: Specificity of Action Within the Haemopoietic System
por: Lord, B. I., et al.
Publicado: (1974)